Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies

Innovent Biologics' Clinical Trial Announcement: Innovent Biologics has completed the first patient dosing of IBI3020, a dual-payload CEACAM5 ADC, in a Phase 1 clinical trial targeting advanced solid tumors, marking it as the first dual-payload ADC globally to reach this milestone.

Study Objectives and Safety Profile: The open-label study aims to evaluate the safety, tolerability, and preliminary efficacy of IBI3020 while determining the recommended Phase 2 dose, with preclinical studies indicating robust antitumor activity and a favorable safety profile.